JPWO2021001508A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021001508A5
JPWO2021001508A5 JP2021577856A JP2021577856A JPWO2021001508A5 JP WO2021001508 A5 JPWO2021001508 A5 JP WO2021001508A5 JP 2021577856 A JP2021577856 A JP 2021577856A JP 2021577856 A JP2021577856 A JP 2021577856A JP WO2021001508 A5 JPWO2021001508 A5 JP WO2021001508A5
Authority
JP
Japan
Prior art keywords
rilpivirine
pharmaceutically acceptable
acceptable salt
subject
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021577856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538338A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/068734 external-priority patent/WO2021001508A1/fr
Publication of JP2022538338A publication Critical patent/JP2022538338A/ja
Publication of JPWO2021001508A5 publication Critical patent/JPWO2021001508A5/ja
Pending legal-status Critical Current

Links

JP2021577856A 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 Pending JP2022538338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870,413 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (fr) 2019-07-03 2020-07-02 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Publications (2)

Publication Number Publication Date
JP2022538338A JP2022538338A (ja) 2022-09-01
JPWO2021001508A5 true JPWO2021001508A5 (fr) 2023-07-11

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577856A Pending JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2021577871A Pending JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021577871A Pending JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Country Status (13)

Country Link
US (3) US20210000823A1 (fr)
EP (2) EP3993799A1 (fr)
JP (2) JP2022538338A (fr)
KR (2) KR20220028049A (fr)
CN (2) CN114126655A (fr)
AU (2) AU2020300818A1 (fr)
BR (2) BR112021026916A2 (fr)
CA (2) CA3144534A1 (fr)
IL (1) IL289457A (fr)
JO (1) JOP20210347A1 (fr)
MA (2) MA56449A (fr)
MX (2) MX2022000060A (fr)
WO (2) WO2021001508A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
CN106511357A (zh) * 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
CA2921336A1 (fr) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Formulations pharmaceutiques
WO2019003150A2 (fr) * 2017-06-30 2019-01-03 Viiv Healthcare Company Association, utilisations et schémas thérapeutiques

Similar Documents

Publication Publication Date Title
JP7525976B2 (ja) ウイルス予防治療方法及び曝露前予防キット
WO2016036759A1 (fr) Méthodes de traitement ou de prévention du vih chez des patients au moyen d'une combinaison de ténofovir alafénamide et de dolutégravir
CA3131159A1 (fr) Traitement de l'herpes simplex avec une combinaison de valacyclovir et famciclovir
Taha et al. Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection
Maugh Chemotherapy: Antiviral agents come of age
AU2023202607A1 (en) Integrase inhibitors for the prevention of HIV
WO2019084020A1 (fr) Méthodes de traitement de patients co-infectés par un virus et la tuberculose
Coyle et al. Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
JP2000513331A (ja) 鬱病の治療におけるパロキセチン
WO2018005909A1 (fr) Combinaisons, utilisations et traitements correspondants
EP3655106A1 (fr) Polythérapie
JPWO2021001508A5 (fr)
JP2020528409A5 (fr)
JP2023526754A (ja) Ｃｏｖｉｄ および ｃｏｖｉｄ－１９ の予防と治療の方法
JPWO2021001568A5 (fr)
TW202210080A (zh) 包含比替拉韋(bictegravir)之醫藥組合物
RU2022102380A (ru) Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина
Kobayashi et al. A case of under-dosing after raltegravir formulation change in an elderly patient treated for HIV
JP2023527798A (ja) ＣＯＶＩＤ－１９（ＳＡＲＳ－ＣｏＶ－２）を含むＲＮＡウイルス感染を治療するための方法
Salunkhe et al. Exploring the Realm of Nanotechnology in HIV and COVID-19
Bowersox ACTG 343: three drugs better than two for maintaining HIV suppression
Francisco Data Released from Startmrk Study of Isentress Versus Efavirenz
Correia de Abreu et al. Single-Tablet Regimen containing Elvitegravir in an HIV-2 Infected Patient
Flamm et al. Comparison of gastrointestinal adverse events of darunavir/ritonavir and lopinavir/ritonavir at Week 96 in ARTEMIS
EP3377177A2 (fr) Formulations d'inhibiteurs de maturation du vih